消费NSAID对细胞癌预后的影响:基于人口的研究
Ilkka Kemppinen1, Antti Pöyhönen1, Priit Veskimäe1
1Tampere University, Fauculty of Medicine and Health Technology, Tampere, Finland.
Clinical genitourinary cancer
|March 6, 2025
概括
在诊断细胞癌 (RCC) 之前使用非类固醇抗炎药物 (NSAID) 会略微增加死亡率. 对于女性来说,这种风险更高,在诊断前和诊断后,NSAID使用与增加RCC死亡率有关.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 非类固醇抗炎药物 (NSAIDs) 广泛用于治疗疼痛和炎症.
- 它们对癌症预后的影响,特别是细胞癌 (RCC),需要进一步调查.
研究的目的:
- 调查NSAID消费与细胞癌 (RCC) 预后之间的关联.
- 为了确定NSAID使用是否影响RCC患者的死亡率.
主要方法:
- 一项回顾性队列研究包括了7492名在1995年至2015年期间被诊断患有RCC的患者.
- 根据NSAID使用情况 (包括乙盐酸[ASA]和COX-2选择性抑制剂[COXIBs]) 将患者分类.
- 使用考克斯回归的多变量分析评估了RCC死亡率的危险比率.
主要成果:
- 在RCC诊断之前使用任何NSAID与死亡率略有增加有关 (HR 1.08).
- 对于单独使用ASA或COXIBs的诊断前或诊断后使用,没有发现显著的关联.
- 在女性中,NSAID使用在诊断前 (HR 1.21) 和诊断后 (HR 1.15) 增加了RCC死亡率.
结论:
- 预诊断的NSAID消费显示了RCC死亡率的适度增加.
- 诊断前和诊断后的NSAID使用都与增加RCC死亡率有关,特别是在女性中.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Drugs for Treatment of Ulcerative Colitis in IBD
116
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
116
Peptic Ulcer Disease IV: Management
57
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
57
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
325
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
325
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


